Avecho Biotechnology Limited
AVEFF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | -0.01 | 0.18 | -0.31 |
| FCF Yield | -65.88% | -477.67% | -12.99% | -26.63% |
| EV / EBITDA | -1.62 | 1.44 | -5.70 | -3.10 |
| Quality | ||||
| ROIC | -110.31% | -70.03% | -114.71% | -98.28% |
| Gross Margin | 64.39% | -9.25% | 72.14% | 64.00% |
| Cash Conversion Ratio | – | 0.93 | 0.71 | 0.91 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.38% | -15.81% | 46.36% | -42.79% |
| Free Cash Flow Growth | -24.80% | -85.06% | 47.95% | -131.15% |
| Safety | ||||
| Net Debt / EBITDA | 0.44 | 1.64 | 0.58 | 1.06 |
| Interest Coverage | -83.96 | -298.84 | -482.60 | -456.24 |
| Efficiency | ||||
| Inventory Turnover | 3.35 | 5.33 | 0.84 | 1.45 |
| Cash Conversion Cycle | 694.52 | 849.07 | 228.88 | 673.64 |